Landos Biopharma Inc (LABP)

NASDAQ
0.25
+0.01(+2.12%)
After Hours
0.25
0.00(1.63%)
- Real-time Data
  • Volume:
    164,223
  • Day's Range:
    0.23 - 0.25
  • 52 wk Range:
    0.21 - 7.23

LABP Overview

Prev. Close
0.24
Day's Range
0.23-0.25
Revenue
-
Open
0.24
52 wk Range
0.21-7.23
EPS
-1.35
Volume
164,223
Market Cap
10.06M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
288,021
P/E Ratio
-0.208
Beta
0.666
1-Year Change
-96.17%
Shares Outstanding
40,254,890
Next Earnings Date
Mar 23, 2023
What is your sentiment on Landos Biopharma?
or
Market is currently closed. Voting is open during market hours.

Landos Biopharma Inc News

Landos Biopharma Inc Company Profile

Landos Biopharma Inc Company Profile

Employees
46

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company’s lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer’s disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Read More

Analyst Price Target

Average2.73 (+993.32% Upside)
High6
Low0.2
Price0.25
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • Insiders are Buying https://www.marketbeat.com/stocks/NYSE/ANTM/insider-trades/
    0
    • insiders loading up on this!!
      0
      • from where you got this info ? from Sec 4 ?
        0
      • did you bought on this share Mr. Li ? to invest in LABP ? what is your opinion please ?
        0
    • insiders loading up on this!!
      0
      • i think will not rise up what is doing this company why to go to $20 yes tell us the reason , like this to jump why ?
        1
        • It is gonna reach to $20 end of Feb
          0
          • Reason?
            0